Researchers from Nitto Denko reported a bispecific siRNA design that simultaneously knocks down two genes—YAP1 and WWTR1 (TAZ)—in the Hippo pathway, aiming to overcome redundancy that enables cancer cells to evade single‑target therapies. The approach, detailed in Molecular Therapy Nucleic Acids, showed robust dual‑gene silencing and phenotypic effects in preclinical models. Authors argued that dual targeting reduces compensatory resistance and can be deployed against networked oncogenic drivers. The team described delivery approaches and candidate optimization to balance potency and off‑target risk. The work advances RNAi therapeutic design toward multi‑node targeting and will interest companies developing siRNA platforms, delivery technologies, and combination nucleic‑acid strategies for oncology and other complex diseases.